News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
nivolumab opdivo

Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.

Read Source